Medical silicone gel for scar repair as well as preparation method and application of medical silicone gel

By using modified silicone gels composed of cyclic silicone, polysiloxane polymer and hyaluronic acid, the problems of difficulty in applying and weak adhesion of silicone gel products are solved, providing pressure and reduction The effect of scaling significantly improves the effect and safety of scar repair.

CN118987337AActive Publication Date: 2024-11-22ZHONGSHAN HOSPITAL FUDAN UNIV +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202411117587.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-22
Estimated Expiration
2044-08-15

AI Technical Summary

Technical Problem

Existing silicone gel products have problems such as difficulty in applying, difficulty in cleaning, weak adhesion, easy to break and inability to provide pressure-relieving effects, resulting in poor scar repair results.

Method used

Medical silicone gels composed of cyclic silicone, polysiloxane polymer, hyaluronic acid and modified silicone are modified by crosslinking polymers and biologically active groups to improve adhesion and Membrane and water retention effect, providing pressure and tension reduction effects.

Benefits of technology

A silicone gel that is stable, non-cytotoxic, and skin-free is easy to apply and clean, enhances scar repair effects, and inhibits excessive scar hyperplasia and collagen deposition.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118987337A_ABST
    Figure CN118987337A_ABST
Patent Text Reader

Abstract

The invention discloses medical silicone gel for scar repair and a preparation method and application thereof, and belongs to the technical field of biomedical materials and tissue engineering. The medical silicone gel is prepared from components in percentage by mass as follows: 1%-10% of cyclic siloxane, 30%-50% of silicone, 10%-30% of a polysiloxane polymer, 1%-10% of a gel matrix and the balance of water. The silicone gel provided by the invention is stable in property, free of cytotoxicity and skin irritation, easy to smear, good in film-forming property and strong in adhesive force with skin tissues, has tension reducing and pressurizing effects on scars, and has a scar repairing effect superior to that of commercially available products.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedical materials and tissue engineering, and specifically relates to a medical silicone gel for scar repair and a preparation method and application thereof. Background Art

[0002] Obvious skin wounds, such as those caused by external force, surgery, etc., can lead to scar formation. Scars are a general term for the appearance and histopathological changes of normal skin tissue caused by various traumas. Scars are mainly characterized by tissues that are significantly higher than the surrounding normal skin, with a red or purple surface, local thickening and hardening, and itchy and painful sensations. In many cases, scars can lead to reduced tactile sensation, loss of flexibility, and loss of range of motion. In addition, scars on exposed skin areas such as the face can lead to obvious aesthetic problems. Therefore, there is a need for treatment methods and means to minimize or eliminate scars.

[0003] Normally, wound dressings made of cotton gauze or various polymers are used clinically to care for skin wounds. Existing wound dressings cannot provide a closed and moist repair environment for the wound, and often cause problems such as infection and scar hyperplasia. In addition, conventional wound dressings are not suitable for wound care at joints or irregular locations, and medical tape is required to fix the dressings, which not only affects the patient's normal activities, but also causes aesthetic problems.

[0004] Silicone gel is a commonly used product for scar repair, and its main component is dimethyl silicone oil (silicone). The mechanism by which silicone gel reduces the appearance of scars is still unclear, but it is speculated that it provides a closed and moist environment for scar tissue, including increased hydration, pH control, temperature increase, and oxygen tension control, which partially improves the fibroblasts and collagen cells in scar tissue.

[0005] However, conventional silicone gel products have the following defects: 1. Most of them are oily products, which are difficult to apply and difficult to clean after application. For patients with large-area skin injuries, pressure is required for application and cleaning, which causes strong pain to the patients; 2. Silicone gel has weak adhesion to the skin. When subjected to external friction, it is easily damaged and falls off due to scratches, and loses its function; 3. Silicone gel is soft in texture and has weak adhesion to the skin. It cannot bring pressure and tension relief to the scar that needs to be repaired, affecting the scar repair effect. Summary of the invention

[0006] In order to improve the defects of the prior art, the present invention provides a medical silicone gel for scar repair, the gel has stable storage performance, no cytotoxicity, and no skin irritation; the gel has strong adhesion to the skin, provides mild pressure and barrier effect for the scar part, and has a tension-reducing effect on the scar part, interferes with the synthesis and deposition of collagen in the scar part, and inhibits excessive scar proliferation. The silicone gel provided by the present invention is easy to form a film and easy to clean, which solves the problem of difficult cleaning and application of conventional products on the market, and alleviates the pain of patients caused by drug replacement during long-term treatment.

[0007] If not specifically explained, the scars described in the present invention include, but are not limited to, pathological scars caused by burns, trauma, surgery, and hypertrophic scars caused by skin trauma, and do not include open wounds or unhealed wounds.

[0008] The present invention includes the following technical solutions:

[0009] In a first aspect, the present invention provides a medical silicone gel, which comprises the following components in percentage by mass: 1-10% cyclic siloxane, 30-50% silicone, 10-30% polysiloxane polymer, 1-10% gel matrix, and the remainder is water.

[0010] The polysiloxane polymer is obtained by cross-linking and polymerizing polymethyl hydrogen siloxane and vinyl polysiloxane prepolymer under platinum catalysis, wherein the vinyl polysiloxane prepolymer is obtained by polymerizing cyclosiloxane and methyl vinyl cyclosiloxane under acid or base catalysis.

[0011] Preferably, the cyclosiloxane is selected from one or a combination of two or more of octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, and dodecamethylcyclohexasiloxane; and the methylvinylcyclosiloxane is selected from one or a combination of two or more of tetramethyltetravinylcyclotetrasiloxane, pentamethylpentavinylcyclopentasiloxane, and hexamethylhexavinylcyclohexasiloxane.

[0012] In a specific embodiment of the present invention, the polysiloxane polymer is prepared by the following method:

[0013] a1) under base catalysis, cyclosiloxane and methylvinylcyclosiloxane are added to a reaction kettle in a mass ratio of 1:(1-3), the temperature is raised to 60-90° C. under nitrogen protection, the reaction is carried out at a constant temperature for 2-3 hours, and water is removed by distillation under reduced pressure to obtain a transparent oily vinyl polysiloxane prepolymer;

[0014] a2) adding the vinyl polysiloxane prepolymer and polymethyl hydrogen siloxane into a reaction kettle in a mass ratio of 1:1, adding a platinum catalyst, raising the temperature to 60-65° C. under nitrogen protection, keeping the temperature to react overnight, extracting with methanol, and the oily substance is a polysiloxane polymer.

[0015] Preferably, the base catalyst in step a1) is potassium hydroxide or tetramethylammonium hydroxide.

[0016] Preferably, the cyclosiloxane in step a1) is dodecamethylcyclohexasiloxane, and the methylvinylcyclosiloxane is hexamethylhexavinylcyclohexasiloxane.

[0017] In a specific embodiment of the present invention, the platinum catalyst is Karstedts catalyst.

[0018] The gel matrix is ​​hyaluronic acid or a hyaluronic acid derivative.

[0019] In a specific embodiment of the present invention, the gel matrix is ​​selected from hyaluronic acid with a molecular weight of 10-20K.

[0020] The cyclic siloxane is selected from one or a combination of two or more of hexamethylcyclotrisiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane.

[0021] In a preferred embodiment of the present invention, the cyclic siloxane is octamethylcyclotetrasiloxane.

[0022] The silicone described in the present invention is polydimethylsiloxane with a viscosity between 100-500 cSt.

[0023] In a preferred embodiment of the present invention, the silicone gel comprises the following components, measured by mass percentage: 5-10% octamethylcyclotetrasiloxane, 40-50% silicone, 20-30% polysiloxane polymer, 5-10% hyaluronic acid, and the balance is water.

[0024] In a specific embodiment of the present invention, the silicone is preferably a modified silicone, and the modified silicone is prepared by the following method:

[0025] Under nitrogen atmosphere, polymethylhydrogensiloxane was added into the reaction kettle, and the modifier was slowly added under stirring. The catalyst Karstedts catalyst was dissolved in toluene and slowly added dropwise into the reaction kettle. The temperature was raised to 60-65° C. and the reaction was kept warm overnight. The oily substance was extracted with methanol and the modified silicone was obtained.

[0026] The modifier is methoxy polyethylene glycol monoacrylate, the structural formula is The average molecular weight is 480, and n is an integer between 8-11.

[0027] Preferably, the mass ratio of polymethylhydrogensiloxane to modifier is 1:(1-1.5).

[0028] In the most preferred embodiment of the present invention, the silicone gel comprises the following components, calculated by mass percentage: 10% octamethylcyclotetrasiloxane, 40-50% modified silicone, 20-30% polysiloxane polymer, 10% hyaluronic acid, and the balance is water.

[0029] Furthermore, the silicone gel also includes 0.1-1% menthol and / or 0.1-1% ascorbic acid.

[0030] In a second aspect, the present invention provides a method for preparing a medical silicone gel, the method comprising the following steps:

[0031] b1) mixing the water and the gel matrix thoroughly under stirring to form a homogeneous medium;

[0032] b2) adding cyclic siloxane and polysiloxane polymer to silicone and mixing well;

[0033] b3) adding the mixed solution of (2) to the homogeneous medium of (1) under stirring, adjusting the pH value to 6.0-7.0, stirring evenly to form a gel state, performing ultrasonic degassing, and packaging for storage.

[0034] In a third aspect, the present invention provides a use of a medical silicone gel in at least one of the following:

[0035] c1) Application in the preparation of materials for scar repair;

[0036] c2) Application in the preparation of antibacterial dressings;

[0037] c3) Application in the preparation of medical devices.

[0038] The medical silicone gel provided by the present invention has the following technical advantages:

[0039] The silicone gel provided by the present invention has good storage stability, no cytotoxicity, no skin irritation, is easy to apply, and has good film-forming properties, so that the gel is easy to operate during application and dressing change, and the scar repair effect is better than that of commercially available products.

[0040] The polysiloxane polymer prepared by the present invention is a cross-linked polysiloxane compound, which has good film-forming property as a gel component, can increase the adhesion of the gel film to the skin, can reduce the pulling of external tension on the wound site, can prevent the scar from becoming wider and larger due to the influence of external force, and as the gel film loses water and shrinks, it has an inward pulling effect on the skin of the scar site, has a pressurizing and tension-reducing effect on the scar site, affects the arrangement of collagen in the scar site, and inhibits excessive scar proliferation.

[0041] The present invention uses active group-modified silicone. The bioactive group-modified silicone has better hydrophilicity, which makes the silicone gel have better water retention effect, reduces the stimulation of water loss on fibroblasts, inhibits the proliferation and expansion of scar tissue, and the modified silicone can also increase the adhesion between the gel film and the skin tissue.

[0042] The aqueous solution of hyaluronic acid is a viscoelastic fluid. Hyaluronic acid has good moisturizing and water-retaining effects on skin scar tissue. The present invention selects hyaluronic acid as a medium to disperse silicone and other polysiloxane materials. Compared with conventional silicone gel, it has a higher degree of moisture and is easier to apply. In addition, a large number of hydrophilic groups in hyaluronic acid have a positive effect on promoting tissue repair and reducing tissue fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 Schematic diagram of the rabbit skin irritation test model.

[0044] Figure 2 Polysiloxane polymer prepared in Preparation Example 1 1 H NMR characterization.

[0045] Figure 3 Modified silicone prepared in Preparation Example 4 1 H NMR characterization.

[0046] Figure 4 Pictures of the incision site on days 0, 14, and 21 after surgery.

[0047] Figure 5 Statistical chart of scar elevation index (SEI) in animal experiments. DETAILED DESCRIPTION

[0048] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only some embodiments of the present invention, not all. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0049] Preparation of polysiloxane polymers

[0050] The synthetic route of the polysiloxane polymer is as follows:

[0051] Step 1:

[0052]

[0053] Step 2:

[0054]

[0055] Preparation Example 1

[0056] S1: With KOH as a catalyst (1 g), 200 g of octamethylcyclotetrasiloxane and 200 g of tetramethyltetravinylcyclotetrasiloxane were added into a reaction kettle under nitrogen protection, the temperature was raised to 90°C, the reaction was carried out at a constant temperature for 3 hours, and the water was removed by distillation under reduced pressure to obtain a transparent oily polysiloxane prepolymer;

[0057] S2: The oily polysiloxane prepolymer obtained in step S1 and the same mass of polymethylhydrogensiloxane are simultaneously put into a reaction kettle, and Karstedts catalyst solution is slowly added. The temperature is raised to 60°C under nitrogen protection, and the temperature is kept for reaction overnight. After cooling to room temperature, cold methanol is added for extraction, and the oily substance is taken and subjected to 1 H NMR characterization, the results are as follows Figure 2 As shown, a characteristic peak of Si-CH3 appears at 0.1-0.3ppm, a characteristic peak of -CH2-CH2- appears at about 0.8ppm, and the characteristic peak of CH2=CH2 of the polysiloxane prepolymer obtained in the first step disappears at about 5.0ppm, indicating that the target product polysiloxane polymer 1 is synthesized.

[0058] Preparation Example 2

[0059] The preparation method and synthesis conditions are the same as those in Preparation Example 1. The same mass (200 g) of decamethylcyclopentasiloxane and pentamethylpentavinylcyclopentasiloxane are reacted under KOH catalysis to obtain a polysiloxane prepolymer. The prepared polysiloxane prepolymer is used as a raw material and reacted with the same mass of polymethylhydrogensiloxane under Karstedts catalyst catalysis overnight. The mixture is extracted with methanol to obtain an oily substance as polysiloxane polymer 2.

[0060] Preparation Example 3

[0061] The preparation method and synthesis conditions are the same as those in Preparation Example 1. The same mass (200 g) of dodecamethylcyclohexasiloxane and hexamethylhexavinylcyclohexasiloxane are used to react under KOH catalysis to obtain a polysiloxane prepolymer. The prepared polysiloxane prepolymer is used as a raw material and reacted with the same mass of polymethylhydrogensiloxane under Karstedts catalyst catalysis overnight, and extracted with methanol to obtain an oily substance as polysiloxane polymer 3. The nuclear magnetic resonance characterization diagrams of the product polysiloxane polymers obtained in Preparation Examples 1-3 of the present invention are similar. In order to save space, the present invention only reflects the nuclear magnetic resonance characterization results of the product of Preparation Example 1.

[0062] Preparation of modified silicone

[0063] Preparation Example 4

[0064] The synthetic route of the modified silicone is as follows:

[0065]

[0066] Under nitrogen atmosphere, 400 g of polymethylhydrogensiloxane was added to the reactor, and the same mass of methoxypolyethylene glycol monoacrylate was slowly added under stirring. The catalyst Karstedts catalyst was dissolved in toluene, and the catalyst solution was slowly added dropwise to the reactor. The temperature was raised to 60°C, and the reaction was kept overnight. After cooling to room temperature, cold methanol was added for extraction, and the oily substance was taken and subjected to 1 H NMR characterization, the results are as follows Figure 3 As shown, a characteristic peak of Si-CH3 appears at 0.1-0.3 ppm, a characteristic peak of -CH2-CH2- connected to the carbonyl group appears between 1.0-2.0 ppm, and a characteristic peak of -O-CH3 appears between 3.0-4.0 ppm, indicating that methoxy polyethylene glycol monoacrylate is coupled to the polymethyl hydrogen siloxane structure to form a crosslink to prepare the modified silicone.

[0067] Preparation of medical silicone gel

[0068] Example 1

[0069] S1: Dissolve 10 parts of hyaluronic acid (molecular weight 20K) in 10 parts of deionized water by mass and mix thoroughly to form a homogeneous hyaluronic acid solution;

[0070] S2: According to the parts by mass, 10 parts of octamethylcyclotetrasiloxane, 30 parts of the polysiloxane polymer 1 prepared in Preparation Example 1 and 40 parts of silicone (viscosity of 200 cSt) were thoroughly mixed under stirring;

[0071] S3: Slowly add the mixed solution of step S2 to the hyaluronic acid solution of step S1 under stirring, adjust the pH to about 7 with triethylamine, and the mixture is in a gel state, ultrasonically degassing, and encapsulating to form a gel preparation.

[0072] Example 2

[0073] The preparation method and raw materials are the same as those in Example 1, except that the polysiloxane polymer 1 prepared in Preparation Example 1 in step S2 is replaced by the polysiloxane polymer 2 prepared in Preparation Example 2 of the same mass.

[0074] Example 3

[0075] The preparation method and raw materials are the same as those in Example 1, except that the polysiloxane polymer 1 prepared in Preparation Example 1 in step S2 is replaced by the polysiloxane polymer 3 prepared in Preparation Example 3 of the same mass.

[0076] Example 4

[0077] The preparation method and raw materials are the same as those in Example 1, except that 40 parts of silicone in step S2 are replaced by the same mass of modified silicone prepared in Preparation Example 4 of the present invention.

[0078] Example 5

[0079] The preparation method and raw materials are the same as those in Example 2, except that 40 parts of silicone in step S2 are replaced by the same mass of modified silicone prepared in Preparation Example 4 of the present invention.

[0080] Example 6

[0081] The preparation method and raw materials are the same as those in Example 3, except that 40 parts of silicone in step S2 are replaced by the same mass of modified silicone prepared in Preparation Example 4 of the present invention.

[0082] Comparative Example 1

[0083] The preparation method and raw materials are the same as those in Example 1, except that the polysiloxane polymer prepared in Preparation Example 1 in step S2 is replaced by silicone (viscosity of 200 cSt) of the same mass.

[0084] Biosafety evaluation of the medical silicone gel prepared by the present invention

[0085] Experiment 1 Cytotoxicity Assay

[0086] Detection method:

[0087] Step 1: Referring to GB / T 16886.12-2017-2017 Biological Evaluation of Medical Devices Part 12: Sample Preparation and Reference Materials, the silicone gels prepared in Examples 1-6 and Comparative Example 1 were extracted with DMEM serum-free medium at a volume-mass ratio of 1 mL: 0.1 g. The extraction conditions were room temperature for 36 h. After extraction, the silicone gels were filtered and sterilized with a 0.22 μm filter membrane for later use.

[0088] Step 2: Human epidermal HaCaT cells in the logarithmic growth phase were taken, digested, and prepared into a concentration of 5×10 4 1. Cell suspension of 100 μg / mL was inoculated into 96-well plates at 200 μL per well. After the cells were completely attached to the wall, the old culture medium was removed and the extract obtained in step 1 (200 μL) was added respectively. Five replicate wells were set for each extract, and a blank control was set. The plates were cultured for 24 h under normal conditions.

[0089] Step 3: Aspirate the solution in the well plate, add 200 μL CCK-8 diluent, continue incubation for 1 hour, detect the absorbance value of the liquid in each well at 450 nm with an enzyme-linked immunosorbent assay, and calculate the cell proliferation rate.

[0090] Cell proliferation rate (%) = (absorbance measurement value of experimental group / absorbance measurement value of blank control group) × 100%

[0091] According to the cytotoxicity evaluation grade table specified in the United States Pharmacopoeia shown in Table 1, the toxicity of the medical silicone gel prepared in Examples 1-6 of the present invention and Comparative Example 1 was evaluated. The results are shown in Table 2.

[0092] Table 1 Cytotoxicity evaluation grade table

[0093]

[0094]

[0095] Table 2 Cytotoxicity evaluation of materials prepared by the present invention

[0096] Extract source Cell proliferation rate (%) Toxicity classification Toxicity evaluation Example 1 Gel 100.3±5.4 0 qualified Example 2 Gel 101.9±4.9 0 qualified Example 3 Gel 93.2±6.2 1 qualified Example 4 Gel 97.4±5.7 1 qualified Example 5 Gel 90.6±7.7 1 qualified Example 6 Gel 92.5±4.0 1 qualified Comparative Example 1 Gel 105.3±3.1 0 qualified

[0097] From the cell proliferation rate data in Table 2, it can be seen that the proliferation rate of HaCaT cells cultured using the medical silicone gel extract prepared in the embodiment of the present invention is above 90%, and is divided into level 0 or level 1 according to the cytotoxicity grade evaluation table, and the toxicity evaluation is qualified, indicating that the medical silicone gel prepared in the embodiment of the present invention has no cytotoxicity and good cell biocompatibility. In addition, under the microscope, the cells in all experimental groups are still polygonal epithelial cells, growing evenly attached to the wall, and no cell morphology occurs.

[0098] Experiment 2 Skin irritation test

[0099] According to the requirements of GB / T 16886.10-2005 / ISO 10993-10:2002, Biological Evaluation of Medical Devices Part 10: Irritation and Delayed Hypersensitivity Test, the irritation of the medical silicone gel prepared in Examples 1-6 of the present invention to the skin was tested. Two healthy, newly grown albino rabbits were used as test subjects and were raised in accordance with the provisions of GB / T16886.2. The hair on both sides of the spine on the back of the animals was removed 4-24 hours before the test (about 10cm×15cm area) as the test and observation site. The test gel 1-6 was directly applied to the skin. Figure 1 The marked skin positions and the remaining marked positions are all observation positions, and physiological saline is applied. The reaction of the marked skin positions is observed under natural light, and the skin reaction of each provoked position at 24h, 48h, and 72h is observed and recorded and scored according to the scoring system given in Table 3. The scoring results are shown in Table 4.

[0100] Table 3 Skin reaction scoring system

[0101]

[0102] Table 4 Skin irritation reaction of medical silicone gel

[0103]

[0104]

[0105] According to the skin irritation reaction scoring results recorded in Table 4, it can be seen that the medical silicone gels prepared in Examples 1-6 of the present invention do not cause skin edema during application. Within 24 hours after application, slight erythema will appear on the skin of the application site, but it will disappear 48 hours after application. The above results can be combined to prove that the silicone gel prepared by the present invention has no skin irritation.

[0106] Tissue adhesion test of the medical silicone gel prepared by the present invention

[0107] Experiment 3 Tissue adhesion strength test

[0108] The present invention uses an in vitro bursting pressure test model to evaluate the adhesion strength of the medical silicone gel prepared by the present invention to biological tissue. The in vitro bursting pressure test is performed according to ASTM F2392-04 (Standard Test Method for Bursting Strength of Surgical Sealants). The principle of the test is to measure the maximum bursting pressure that can be maintained by the silicone gel after film formation at the tissue leakage point.

[0109] Test method:

[0110] Imitation of skin tissue substrate, a hole with a diameter of 3.0 mm was made on the surface of a collagen casing with a thickness of about 0.1-0.5 mm, and a syringe was used to apply 500 μL of the medical silicone gel to be tested to the hole of the collagen casing to seal the hole, forming a coating layer with a thickness equivalent to that of the collagen casing, and the film was left to stand at room temperature for 10-15 minutes until the gel was formed, and the collagen casing to be tested was placed on the test unit, and a digital pressure gauge was used to record the pressure when the silicone gel film ruptured as the maximum bursting pressure. The silicone gels prepared in Examples 1-6 of the present invention and Comparative Example 1 were tested respectively, and 10 parallel samples were made for each gel. The test results are shown in the following table:

[0111] Table 5 Burst pressure test of medical gel

[0112]

[0113]

[0114] The difference between the silicone gel prepared in Comparative Example 1 and Example 1 is that the polysiloxane polymer 1 prepared by the present invention is replaced with conventional silicone of the same mass. From the bursting pressure results obtained by detection, it can be seen that the polysiloxane polymer 1 prepared by the present invention has the effect of significantly increasing the bursting pressure of the gel compared with conventional silicone. The inventor analyzed the reasons and believed that the polysiloxane polymer prepared by the present invention has good film-forming properties and stronger adhesion to skin tissue. Therefore, compared with conventional silicone, the gel film with the addition of the polysiloxane polymer has stronger pressure resistance and the detected bursting pressure value is larger.

[0115] The difference between the silicone gels prepared in Examples 1 to 3 of the present invention is that the addition reaction monomers forming the polysiloxane polymer are different. From the bursting pressure test results, it can be seen that the gel of Example 3 has better compression resistance and stronger adhesion to skin tissue, indicating that the polysiloxane polymer used in Example 3 has better effect, and the polysiloxane prepolymer obtained by ring-opening polymerization of dodecamethylcyclohexasiloxane and hexamethylhexavinylcyclohexasiloxane is essentially better. The technicians analyzed the reason and believed that it may be because compared with tetramethyltetravinylcyclotetrasiloxane, hexamethylhexavinylcyclohexasiloxane will polymerize to form a reaction monomer containing more vinyl groups, and then when it reacts with polymethylhydrogensiloxane, it will form a polysiloxane with a higher cross-linking state, and the polysiloxane will have stronger adhesion to the skin during the film-forming process in contact with skin tissue.

[0116] It can also be seen from the test data in Table 5 that when the conventional silicone in the silicone gel system is replaced with the modified silicone prepared by the present invention, the compressive strength of the gel film can be further improved. This is because compared with conventional silicone, the modified silicone molecule is coupled with methoxy polyethylene glycol monoacrylate units, and a large number of oxygen atoms can form a hydrogen bond-like binding force with the skin surface in a wet environment, so that the adhesion between the gel film and the skin tissue is further enhanced. Based on the above test, the present invention subsequently uses the silicone gel prepared in Examples 4-6 for animal testing.

[0117] Scar repair ability test of the medical silicone gel prepared by the present invention

[0118] Experiment 4: Scar repair ability test

[0119] Test method:

[0120] Twelve rats were randomly divided into four groups, with three rats in each group. The rats were fasted for 12 hours before anesthesia, and 10% chloral hydrate was injected intraperitoneally to induce general anesthesia. After general anesthesia, the back hair on the inner side of the scapula was shaved (4cm×6cm), disinfected with iodine tincture, and then deiodinated with alcohol to reduce skin and mucous membrane irritation. Two circular incisions deep to the fascia were made on both sides of the back of the spine of the 12 rats using a biopsy punch, and the secretions in the wound were cleaned with saline, and the residual liquid was wiped off with sterile gauze.

[0121] After the model was established, conventional dressings were used to cover the incision, and the dressings were changed every 3 days. On the 7th day after surgery, the dressings were removed to expose the wound surface. Starting from the 7th day after surgery, the test side of the 4 groups of rats were coated with the medical silicone gel prepared in Examples 4-6 of the present invention and a commercially available silicone gel, respectively, and the control side was coated with commercially available sterile gauze, all of which were changed every 3 days. Images of the incision were collected on the 14th day and 21st day after surgery, respectively. Among them, the incision recovery photos of the mice in the silicone gel test group in Example 6 are shown in Figure 2. Figure 4 As shown, it can be seen that on the 14th day after surgery, granulation tissue was generated at the edge of the incision on the control side, and there was a certain degree of swelling, but the skin at the incision site on the test side was rapidly epithelialized, and the wound size was significantly smaller than the control. The technicians of the present invention unexpectedly found that the skin on the side using the medical silicone gel tended to be obviously pulled inward, which was more conducive to wound healing. This is because the silicone gel prepared by the present invention has good film-forming properties and skin adhesion. As the gel loses water and shrinks in volume, it has an obvious pullback force on the wound skin, achieving a tension-reducing effect, while sterile gauze cannot achieve this effect at all. On the 21st day after surgery, the scab on the test side fell off, the wound site was neat, and no obvious linear scar appeared, but the scab on the control side had not fallen off, and irregular protrusions appeared on the skin around the scab, forming an obvious scar.

[0122] On the 21st day after surgery, the rats were euthanized, the thickness of scar tissue on one side of the experimental group and the control group was measured, and the SEI at the scar position was calculated. The calculation formula of the scar elevation index (SEI) is as follows:

[0123] SEI=(A+B) / B,

[0124] A is the thickness of scar tissue that is higher than normal epidermis, and B is the thickness of normal epidermis. The test results are shown in the following table.

[0125] Table 6 SEI statistical results of scar sites

[0126]

[0127] From the statistical results of SEI of the scar area of ​​rats, it can be seen that the scar elevation index on the side using the medical silicone gel prepared by the present invention is significantly lower than that on the side using sterile gauze. The inventor analyzed the reason and believed that compared with sterile gauze, the silicone gel prepared by the present invention can provide sterile coverage and water retention and moisturizing to the scar area, which is beneficial to the partial improvement of fibroblasts and collagen in the scar tissue, so that the collagen can be rearranged close to normal skin, fibrosis can be inhibited and scar formation can be reduced. In addition, another important reason is that the silicone gel provided by the present invention has a strong adhesion to the skin after forming a film. When the volume of the gel decreases due to water loss, there is an inward pulling force on the scar area of ​​the skin, which has a tension-relieving effect on the scar. The strong adhesion also causes the gel film to pressurize the scar area, promoting the orderly rearrangement of collagen in the scar area to be close to normal skin. Moreover, through Figure 5 It can be seen from the SEI statistical results that, compared with commercially available gels, the silicone gel prepared by the present invention has a more significant effect of reducing scar protrusions. Technicians believe that this is related to the tension-reducing and pressure-increasing effects of the silicone gel prepared by the present invention.

[0128] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. A medical silicone gel, characterized in that: The silicone gel comprises the following components in terms of mass percentage: 1-10% cyclic siloxane, 30-50% silicone, 10-30% polysiloxane polymer, 1-10% gel matrix, and the balance is water; The polysiloxane polymer is obtained by cross-linking and polymerizing polymethyl hydrogen siloxane and vinyl polysiloxane prepolymer under platinum catalysis, wherein the vinyl polysiloxane prepolymer is obtained by polymerizing cyclosiloxane and methyl vinyl cyclosiloxane under acid or base catalysis.

2. The medical silicone gel according to claim 1, characterized in that: The cyclosiloxane is selected from one or a combination of two or more of octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane, and dodecamethylcyclohexasiloxane; the methylvinylcyclosiloxane is selected from one or a combination of two or more of tetramethyltetravinylcyclotetrasiloxane, pentamethylpentavinylcyclopentasiloxane, and hexamethylhexavinylcyclohexasiloxane.

3. The medical silicone gel according to claim 2, characterized in that: The polysiloxane polymer is prepared by the following method: a1) under base catalysis, cyclosiloxane and methylvinylcyclosiloxane are added to a reaction kettle in a mass ratio of 1:(1-3), the temperature is raised to 60-90° C. under nitrogen protection, the reaction is carried out at a constant temperature for 2-3 hours, and water is removed by distillation under reduced pressure to obtain a transparent oily vinyl polysiloxane prepolymer; a2) adding the vinyl polysiloxane prepolymer and polymethyl hydrogen siloxane into a reaction kettle in a mass ratio of 1:1, adding a platinum catalyst, heating to 60-65° C. under nitrogen protection, keeping the temperature to react overnight, extracting with methanol, and the oily substance is a polysiloxane polymer; Wherein, the cyclosiloxane described in step a1) is dodecamethylcyclohexasiloxane, and the methylvinylcyclosiloxane is hexamethylhexavinylcyclohexasiloxane.

4. The medical silicone gel according to claim 1, characterized in that: The gel matrix is ​​hyaluronic acid or a hyaluronic acid derivative; the cyclic siloxane is selected from one or a combination of two or more of hexamethylcyclotrisiloxane, octamethylcyclotetrasiloxane, decamethylcyclopentasiloxane and dodecamethylcyclohexasiloxane; and the silicone is polydimethylsiloxane with a viscosity between 100 and 500 cSt.

5. The medical silicone gel according to claim 4, characterized in that: The silicone gel comprises the following components in terms of mass percentage: 5-10% octamethylcyclotetrasiloxane, 40-50% silicone, 20-30% polysiloxane polymer, 5-10% hyaluronic acid, and the balance is water.

6. The medical silicone gel according to claim 5, characterized in that: The silicone is a modified silicone, and the modified silicone is prepared by the following method: Under nitrogen atmosphere, polymethylhydrogensiloxane was added into the reaction kettle, and the modifier was slowly added under stirring. The catalyst Karstedts catalyst was dissolved in toluene and slowly added dropwise into the reaction kettle. The temperature was raised to 60-65° C. and the reaction was kept warm overnight. The oily substance was extracted with methanol, and the modified silicone was obtained. The modifier was methoxy polyethylene glycol monoacrylate.

7. The medical silicone gel according to claim 6, characterized in that: The silicone gel comprises the following components in terms of mass percentage: 10% octamethylcyclotetrasiloxane, 40-50% modified silicone, 20-30% polysiloxane polymer, 10% hyaluronic acid, and the balance is water.

8. The medical silicone gel according to claim 1, characterized in that: The silicone gel further comprises 0.1-1% menthol and / or 0.1-1% ascorbic acid.

9. A method for preparing the medical silicone gel according to any one of claims 1 to 8, comprising the following steps: b1) mixing the water and the gel matrix thoroughly under stirring to form a homogeneous medium; b2) adding cyclic siloxane and polysiloxane polymer to silicone and mixing well; b3) adding the mixed solution of (2) to the homogeneous medium of (1) under stirring, adjusting the pH value to 6.0-7.0, stirring evenly to form a gel state, performing ultrasonic degassing, and packaging for storage.

10. Use of the medical silicone gel according to any one of claims 1 to 8 in at least one of the following: c1) Application in the preparation of materials for scar repair; c2) Application in the preparation of antibacterial dressings; c3) Application in the preparation of medical devices.

Citation Information

Patent Citations

  • Medical silicon rubber with modified hydrophilic structure on surface, and preparation and application of medical silicon rubber

    CN102417602A

  • Silica gel composition for treating scars and resisting skin aging

    CN104784211A

  • Novel topical skin closure compositions and systems

    CN115666784A

  • Organosilicone elastomer, and preparation method, daily chemical product and application thereof

    CN117511220A

  • Silicone gel composition containing hyaluronic acid and / or its salt for prevention and repair of skin scars

    WO2020141986A1